JP2006516618A - アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法 - Google Patents
アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法 Download PDFInfo
- Publication number
- JP2006516618A JP2006516618A JP2006502933A JP2006502933A JP2006516618A JP 2006516618 A JP2006516618 A JP 2006516618A JP 2006502933 A JP2006502933 A JP 2006502933A JP 2006502933 A JP2006502933 A JP 2006502933A JP 2006516618 A JP2006516618 A JP 2006516618A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- adrenergic
- adrenergic agent
- core
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 42
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 40
- 239000000048 adrenergic agonist Substances 0.000 title claims abstract description 34
- 239000000464 adrenergic agent Substances 0.000 claims abstract description 80
- 239000003814 drug Substances 0.000 claims description 297
- 229940079593 drug Drugs 0.000 claims description 295
- 239000010410 layer Substances 0.000 claims description 116
- 229920000642 polymer Polymers 0.000 claims description 69
- 239000011159 matrix material Substances 0.000 claims description 49
- 238000009792 diffusion process Methods 0.000 claims description 45
- 239000011247 coating layer Substances 0.000 claims description 44
- 238000012377 drug delivery Methods 0.000 claims description 38
- -1 levovetaxol Chemical compound 0.000 claims description 23
- 238000003780 insertion Methods 0.000 claims description 19
- 230000037431 insertion Effects 0.000 claims description 19
- 210000001124 body fluid Anatomy 0.000 claims description 17
- 210000004240 ciliary body Anatomy 0.000 claims description 14
- 238000002513 implantation Methods 0.000 claims description 11
- 230000001800 adrenalinergic effect Effects 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 9
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 8
- 239000010839 body fluid Substances 0.000 claims description 8
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 6
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 6
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 6
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 claims description 6
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 claims description 6
- 229960002610 apraclonidine Drugs 0.000 claims description 6
- 229960004324 betaxolol Drugs 0.000 claims description 6
- 229960003679 brimonidine Drugs 0.000 claims description 6
- 229960002467 bunazosin Drugs 0.000 claims description 6
- 229960001222 carteolol Drugs 0.000 claims description 6
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 6
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 6
- 229960001117 clenbuterol Drugs 0.000 claims description 6
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 claims description 6
- 229960000966 dipivefrine Drugs 0.000 claims description 6
- 229960001022 fenoterol Drugs 0.000 claims description 6
- 229960001317 isoprenaline Drugs 0.000 claims description 6
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 6
- 229960000831 levobunolol Drugs 0.000 claims description 6
- 229960002704 metipranolol Drugs 0.000 claims description 6
- 229960004605 timolol Drugs 0.000 claims description 6
- 230000032258 transport Effects 0.000 claims description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 5
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 5
- 229960005139 epinephrine Drugs 0.000 claims description 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 4
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 claims description 3
- 229960004771 levobetaxolol Drugs 0.000 claims description 3
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims 4
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 claims 4
- 238000011282 treatment Methods 0.000 abstract description 11
- 208000010412 Glaucoma Diseases 0.000 abstract description 9
- 239000003246 corticosteroid Substances 0.000 abstract description 4
- 229960001334 corticosteroids Drugs 0.000 abstract description 4
- 230000004406 elevated intraocular pressure Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000011162 core material Substances 0.000 description 113
- 239000000463 material Substances 0.000 description 62
- 239000012530 fluid Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 33
- 239000007787 solid Substances 0.000 description 20
- 239000002202 Polyethylene glycol Substances 0.000 description 18
- 229920001577 copolymer Polymers 0.000 description 18
- 229920001223 polyethylene glycol Polymers 0.000 description 18
- 238000003860 storage Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000035699 permeability Effects 0.000 description 16
- 239000008358 core component Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 239000012458 free base Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 150000003839 salts Chemical group 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 230000004410 intraocular pressure Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 229920002554 vinyl polymer Polymers 0.000 description 9
- 229920002988 biodegradable polymer Polymers 0.000 description 8
- 239000004621 biodegradable polymer Substances 0.000 description 8
- 239000011118 polyvinyl acetate Substances 0.000 description 8
- 229920002689 polyvinyl acetate Polymers 0.000 description 8
- 239000004677 Nylon Substances 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 229920001778 nylon Polymers 0.000 description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 230000005588 protonation Effects 0.000 description 6
- 239000002876 beta blocker Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 239000004632 polycaprolactone Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002861 polymer material Substances 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 3
- 229920000249 biocompatible polymer Polymers 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 239000004709 Chlorinated polyethylene Substances 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- 229920001986 Vinylidene chloride-vinyl chloride copolymer Polymers 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 239000004815 dispersion polymer Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 2
- 239000003604 miotic agent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 2
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 229920001290 polyvinyl ester Polymers 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000181 Ethylene propylene rubber Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241000083513 Punctum Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- VEHZBMGMMPZMRJ-UHFFFAOYSA-N acetic acid;2-(diethylamino)acetic acid Chemical compound CC(O)=O.CCN(CC)CC(O)=O VEHZBMGMMPZMRJ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004509 aqueous humor production Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000012661 block copolymerization Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- IKZZIQXKLWDPCD-UHFFFAOYSA-N but-1-en-2-ol Chemical compound CCC(O)=C IKZZIQXKLWDPCD-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
- 229920006244 ethylene-ethyl acrylate Polymers 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001029 thermal curing Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Nanotechnology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
緑内障は先進国における失明の主原因の一つである。緑内障の主たる病態生理学的特徴は眼圧上昇である。眼圧を下げるための外科手術及び/又は薬物が緑内障の最も一般的な治療法である。今日用いられている主な薬物治療には、小柱網を開いて眼から流体が流れ出る速度を増加させる縮瞳薬(例えば、ピロカルピン、カルバコール及びエコチオフェート);強膜ブドウ膜流を促すPGF−2αアナログ(例えば、ウノプロストン、トラボプロスト、ビマトプロスト及びラタノプロスト);並びに、眼へ流体が流れ込む速度を減少させる炭酸脱水酵素阻害剤(例えば、アセタゾラミド、メタゾラミド及びドルゾラミド)の投与がある。
眼への薬物投与に適合したいくつかの徐放性デバイス及び処方物が先行技術に記載されている。コハン(Cohan)及びダイアモンド(Diamond)に発行された米国特許第6,196,993号は、眼の涙小管へ埋植するための眼内インサートを記載している。このデバイスは薬物の内部貯蔵室を有し、薬物が通って拡散することが意図された表面開口部を特徴とする。下瞼と眼の間に設置するのに適合した徐放性システムがネス(Ness)に発行された米国特許第3,416,530号及び第3,618,604号、ザファロニ(Zaffaroni)に発行された同第3,626,940号、アブラハム(Abraham)に発行された同第3,826,258号、ハドダッド(Haddad)及びロウカス(Loucas)に発行された同第3,845,201号、チーウェス(Theeuwes)等に発行された同第3,845,770号、ミッシェル(Michaels)に発行された同第3,962,414号、ヒグチ(Higuchi)等に発行された同第3,993,071号、アーノルド(Arnold)に発行された同第4,014,335号、及びミヤタ(Miyata)に発行された同第4,164,559号に開示されている。ウォン(Wong)に発行された米国特許第5,824,072号には、例えば脈絡膜へ埋植することを意図した、貯蔵室及びポリマーマトリクスの眼内インプラントが記載されている。グウォン(Gwon)等に発行された米国特許第5,476,511号には結膜の下方に埋植するための眼内インプラントが記載されている。ヤーコビ(Yaacobi)に発行された米国特許第6,416,777号には眼の後部にある強膜の外表面に埋植するための眼内インプラントが記載されている。
(i) 少なくとも1種のアドレナリン作動薬を含む内部の薬物コアと;
(ii) 前記少なくとも1種のアドレナリン作動薬の通過に対して不透過性であり、前記少なくとも1種のアドレナリン作動薬が通って拡散することのできる一つ若しくは二つ以上の開口部を有し、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である第一被覆層と;
(iii)前記少なくとも1種のアドレナリン作動薬の通過に対して透過性であり、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である一つ又は二つ以上の追加的な被覆層と;
を備える。
ここで、前記不透過性被覆層及び透過性被覆層は、挿入されたときに、前記デバイスからの前記少なくとも1種のアドレナリン作動薬の放出速度が一定となるように内部コアの周囲に配置される。そのような徐放性デバイスは米国特許第5,378,475号に開示されている。
Q/t = (D・K・A・DC)/h
(式中、Qは薬物の放出量、tは時間、Dは拡散係数、Kは分配係数、Aは表面積、DCは膜間の薬物濃度差、及びhは膜厚である。)
によって与えられる。
P = (K・D)/h
によって関係付けることができる。
Claims (21)
- (i) アドレナリン作動薬を含む内部の薬物コアと;
(ii) 前記アドレナリン作動薬の通過に対して実質的に不透過性であり、前記アドレナリン作動薬の拡散を許容する一つ若しくは二つ以上の開口部を有し、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である、前記薬物コアの表面上の第一被覆層と;
(iii)前記アドレナリン作動薬の通過に対して透過性であり、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である、一つ又は二つ以上の追加的な被覆層と;
を備える患者の眼内又はその近傍への埋植に適合した徐放性薬物輸送デバイス
(ここで、第一及び追加的な被覆層は、埋植されたときに、前記デバイスからの前記アドレナリン作動薬の放出速度を実質的に一定とするために前記内部の薬物コアの周囲に配置される。)。 - (i) アドレナリン作動薬を含む内部の薬物コアと;
(ii) 前記アドレナリン作動薬の通過に対して実質的に不透過性であり、前記アドレナリン作動薬の拡散を許容する一つ若しくは二つ以上の開口部を有し、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である、前記薬物コアの表面上の第一被覆層と;
(iii)前記アドレナリン作動薬の通過に対して透過性であり、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である、一つ又は二つ以上の追加的な被覆層と;
を備える患者の眼内又はその近傍への埋植に適合した徐放性薬物輸送デバイス
(ここで、前記不透過性の被覆層はその形状を変化させずにアドレナリン作動薬のコアで満たされるのに充分な寸法安定性を有する。)。 - 前記不透過性の被覆層はその形状を変化させずにアドレナリン作動薬のコアで満たされるのに充分な寸法安定性を有する請求項1に記載のデバイス。
- 眼の毛様体にアドレナリン作動薬を投与する方法であって、眼内又はその近傍に徐放性デバイスを埋植することを含み、これによって前記デバイスはアドレナリン作動薬を眼の毛様体に輸送し、毛様体内での前記アドレナリン作動薬の濃度は少なくとも30日間は治療上有効な濃度に維持される方法。
- 眼の毛様体にアドレナリン作動薬を投与する方法であって、眼内又はその近傍に請求項1〜3又は14の何れか一項に記載の徐放性デバイスを埋植することを含み、これによって前記デバイスはアドレナリン作動薬を眼の毛様体に輸送し、毛様体内での前記アドレナリン作動薬の濃度は少なくとも30日間は治療上有効な濃度に維持される方法。
- 毛様体内のアドレナリン作動薬の濃度が少なくとも180日間は治療上有効な濃度に維持される請求項4に記載の方法。
- 毛様体内のアドレナリン作動薬の濃度が少なくとも180日間は治療上有効な濃度に維持される請求項5に記載の方法。
- 毛様体内のアドレナリン作動薬の濃度が少なくとも360日間は治療上有効な濃度に維持される請求項4に記載の方法。
- 毛様体内のアドレナリン作動薬の濃度が少なくとも360日間は治療上有効な濃度に維持される請求項5に記載の方法。
- 前記アドレナリン作動薬がブリモニジン、アプラクロニジン、ブナゾシン、チモロール、ベタキソロール、レボベタキソロール、レボブノロール、カルテオロール、イソプレナリン、フェノテロール、メチプラノロール、クレンブテロール、エピネフリン、及びジピベフリンよりなる群から選択される請求項1〜4、6及び8の何れか一項に記載のデバイス。
- 前記アドレナリン作動薬がブリモニジン、アプラクロニジン、ブナゾシン、チモロール、ベタキソロール、レボベタキソロール、レボブノロール、カルテオロール、イソプレナリン、フェノテロール、メチプラノロール、クレンブテロール、エピネフリン、及びジピベフリンよりなる群から選択される請求項5に記載の方法。
- 前記アドレナリン作動薬がブリモニジン、アプラクロニジン、ブナゾシン、チモロール、ベタキソロール、レボベタキソロール、レボブノロール、カルテオロール、イソプレナリン、フェノテロール、メチプラノロール、クレンブテロール、エピネフリン、及びジピベフリンよりなる群から選択される請求項7に記載の方法。
- 前記アドレナリン作動薬がブリモニジン、アプラクロニジン、ブナゾシン、チモロール、ベタキソロール、レボベタキソロール、レボブノロール、カルテオロール、イソプレナリン、フェノテロール、メチプラノロール、クレンブテロール、エピネフリン、及びジピベフリンよりなる群から選択される請求項9に記載の方法。
- (i) 少なくとも1種のアドレナリン作動薬を含む内部の薬物コアと;
(ii) 前記少なくとも1種のアドレナリン作動薬の通過に対して実質的に不透過性であり、前記少なくとも1種のアドレナリン作動薬の拡散を許容する一つ若しくは二つ以上の開口部を有し、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である、前記薬物コアの表面上の被覆層と;
を備える患者の眼内又はその近傍への挿入に適合した徐放性薬物輸送デバイス
(ここで、前記被覆層は、挿入されたときに、前記デバイスからの前記アドレナリン作動薬の放出速度を実質的に一定とするために前記内部の薬物コアの周囲に配置される。)。 - 前記内部の薬物コアはポリマーマトリクスと混合される請求項14に記載の徐放性薬物輸送デバイス。
- 前記ポリマーマトリクスは生分解性である請求項15に記載の徐放性薬物輸送デバイス。
- 前記デバイスが前記内部の薬物コアと前記被覆層を同時押出することによって形成される請求項14に記載の徐放性薬物輸送デバイス。
- (i) 少なくとも1種のアドレナリン作動薬を含む内部の薬物コアと;
(ii) 前記少なくとも1種のアドレナリン作動薬の通過に対して部分的に又は実質的に透過性であり、前記少なくとも1種のアドレナリン作動薬の拡散を助ける一つ若しくは二つ以上の開口部を有し、体液中にて実質的に不溶性及び不活性であり、体組織に適合可能である、前記薬物コアの表面上の被覆層と;
を備える患者の眼内又はその近傍への挿入に適合した徐放性薬物輸送デバイス
(ここで、前記被覆層は、挿入されたときに、前記デバイスからの前記少なくとも1種のアドレナリン作動薬の放出速度を実質的に一定とするために前記内部の薬物コアの周囲に配置される。)。 - 前記内部の薬物コアがポリマーマトリクスと混合される請求項18に記載の徐放性薬物輸送デバイス。
- 前記ポリマーマトリクスが生分解性である請求項19に記載の徐放性薬物輸送デバイス。
- 前記デバイスが前記内部の薬物コアと前記被覆層を同時押出することによって形成される請求項20に記載の徐放性薬物輸送デバイス。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44249903P | 2003-01-24 | 2003-01-24 | |
US48331603P | 2003-06-26 | 2003-06-26 | |
US48267703P | 2003-06-26 | 2003-06-26 | |
US50197403P | 2003-09-11 | 2003-09-11 | |
PCT/US2004/001718 WO2004066979A2 (en) | 2003-01-24 | 2004-01-23 | Sustained release device and method for ocular delivery of adrenergic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006516618A true JP2006516618A (ja) | 2006-07-06 |
Family
ID=32831098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006502933A Pending JP2006516618A (ja) | 2003-01-24 | 2004-01-23 | アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1592408B1 (ja) |
JP (1) | JP2006516618A (ja) |
KR (1) | KR20050118161A (ja) |
AR (1) | AR042917A1 (ja) |
AT (1) | ATE440595T1 (ja) |
AU (1) | AU2004207506B2 (ja) |
BR (1) | BRPI0406879B1 (ja) |
CA (1) | CA2513751C (ja) |
DE (1) | DE602004022776D1 (ja) |
DK (1) | DK1592408T3 (ja) |
ES (1) | ES2332720T3 (ja) |
MX (1) | MXPA05007719A (ja) |
SI (1) | SI1592408T1 (ja) |
TW (1) | TWI356714B (ja) |
WO (1) | WO2004066979A2 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006516619A (ja) * | 2003-01-24 | 2006-07-06 | コントロール・デリバリー・システムズ・インコーポレイテッド | 炭酸脱水酵素阻害剤を眼へ輸送するために徐放性デバイス及び方法 |
JP2008018234A (ja) * | 2006-06-21 | 2008-01-31 | Johnson & Johnson Vision Care Inc | 活性剤の投与のための涙点プラグ |
JP2010505569A (ja) * | 2006-10-09 | 2010-02-25 | フランス シリュージ エストリマタシオン | 適用容易なミータル・プラグ |
JP2010537775A (ja) * | 2007-09-07 | 2010-12-09 | キューエルティー プラグ デリバリー,インク. | 涙管インプラント及び関連する方法 |
JP2011520805A (ja) * | 2008-05-09 | 2011-07-21 | キューエルティー プラグ デリバリー,インク. | 緑内障および高眼圧症治療のための活性剤の持続送達 |
JP2012512725A (ja) * | 2008-12-19 | 2012-06-07 | キュー エル ティー インク. | 物質送達用涙点インプラントおよび物質送達方法 |
JP2012514493A (ja) * | 2009-01-02 | 2012-06-28 | アルコン リサーチ, リミテッド | その場で再充填可能な眼用移植物 |
JP2012228571A (ja) * | 2006-03-31 | 2012-11-22 | Qlt Inc | 鼻涙系用の薬物送達方法、構造および組成物 |
JP2013523821A (ja) * | 2010-04-06 | 2013-06-17 | アラーガン、インコーポレイテッド | 前房内薬剤送達のための徐放性リザーバーインプラント |
KR101341364B1 (ko) | 2006-06-21 | 2013-12-13 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 활성제 전달용 눈물점 마개 |
JP2014236980A (ja) * | 2007-09-07 | 2014-12-18 | キュー エル ティー インク.QLT Inc. | 治療薬剤の持続放出のための薬物コア |
CN110730655A (zh) * | 2017-06-13 | 2020-01-24 | 视点制药公司 | 可生物侵蚀的药物递送装置 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
JP2008504938A (ja) * | 2004-07-02 | 2008-02-21 | レイザー,エリオット | 治療媒体送出装置およびその送出装置を用いて治療媒体を眼に送り出す方法 |
EP2097044A4 (en) * | 2006-12-26 | 2012-10-10 | Quadra Logic Tech Inc | DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS |
US20090264477A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc., An Indiana Corporation | Beta adrenergic receptor agonists for treatment of pain and/or inflammation |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
EP2303184A4 (en) * | 2008-06-24 | 2013-06-19 | Quadra Logic Tech Inc | GLAUCOMA ASSOCIATION TREATMENT |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
PL2498783T3 (pl) | 2009-11-09 | 2019-04-30 | Allergan Inc | Kompozycje i sposoby stymulowania wzrostu włosów |
US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
WO2013011511A1 (en) | 2011-07-18 | 2013-01-24 | Mor Research Applications Ltd. | A device for adjusting the intraocular pressure |
EP2956096A1 (en) | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011244A1 (en) * | 1997-08-28 | 1999-03-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
WO2000062760A1 (en) * | 1999-04-19 | 2000-10-26 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
WO2001080825A2 (en) * | 2000-04-26 | 2001-11-01 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
-
2004
- 2004-01-23 KR KR1020057013643A patent/KR20050118161A/ko not_active Application Discontinuation
- 2004-01-23 JP JP2006502933A patent/JP2006516618A/ja active Pending
- 2004-01-23 ES ES04704837T patent/ES2332720T3/es not_active Expired - Lifetime
- 2004-01-23 AR ARP040100201A patent/AR042917A1/es unknown
- 2004-01-23 DK DK04704837T patent/DK1592408T3/da active
- 2004-01-23 CA CA2513751A patent/CA2513751C/en not_active Expired - Fee Related
- 2004-01-23 AU AU2004207506A patent/AU2004207506B2/en not_active Ceased
- 2004-01-23 BR BRPI0406879A patent/BRPI0406879B1/pt not_active IP Right Cessation
- 2004-01-23 SI SI200431291T patent/SI1592408T1/sl unknown
- 2004-01-23 MX MXPA05007719A patent/MXPA05007719A/es active IP Right Grant
- 2004-01-23 DE DE602004022776T patent/DE602004022776D1/de not_active Expired - Lifetime
- 2004-01-23 AT AT04704837T patent/ATE440595T1/de not_active IP Right Cessation
- 2004-01-23 WO PCT/US2004/001718 patent/WO2004066979A2/en active Application Filing
- 2004-01-23 EP EP04704837A patent/EP1592408B1/en not_active Expired - Lifetime
- 2004-01-27 TW TW093101751A patent/TWI356714B/zh not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011244A1 (en) * | 1997-08-28 | 1999-03-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
WO2000062760A1 (en) * | 1999-04-19 | 2000-10-26 | Eyelab Group, Llc | Ophthalmic insert and method for sustained release of medication to the eye |
WO2001080825A2 (en) * | 2000-04-26 | 2001-11-01 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006516619A (ja) * | 2003-01-24 | 2006-07-06 | コントロール・デリバリー・システムズ・インコーポレイテッド | 炭酸脱水酵素阻害剤を眼へ輸送するために徐放性デバイス及び方法 |
JP2012228571A (ja) * | 2006-03-31 | 2012-11-22 | Qlt Inc | 鼻涙系用の薬物送達方法、構造および組成物 |
JP2008018234A (ja) * | 2006-06-21 | 2008-01-31 | Johnson & Johnson Vision Care Inc | 活性剤の投与のための涙点プラグ |
KR101341364B1 (ko) | 2006-06-21 | 2013-12-13 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 활성제 전달용 눈물점 마개 |
JP2010505569A (ja) * | 2006-10-09 | 2010-02-25 | フランス シリュージ エストリマタシオン | 適用容易なミータル・プラグ |
KR20170005905A (ko) * | 2007-09-07 | 2017-01-16 | 마티 테라퓨틱스 인코포레이티드 | 치료 약제의 서방성 약물 코어 |
KR101696301B1 (ko) | 2007-09-07 | 2017-01-13 | 마티 테라퓨틱스 인코포레이티드 | 치료 약제의 서방성 약물 코어 |
JP2020062381A (ja) * | 2007-09-07 | 2020-04-23 | マティ セラピューティクス,インク. | 治療薬剤の持続放出のための薬物コア |
KR101996336B1 (ko) | 2007-09-07 | 2019-07-04 | 마티 테라퓨틱스 인코포레이티드 | 치료 약제의 서방성 약물 코어 |
JP2010537775A (ja) * | 2007-09-07 | 2010-12-09 | キューエルティー プラグ デリバリー,インク. | 涙管インプラント及び関連する方法 |
JP2014193367A (ja) * | 2007-09-07 | 2014-10-09 | Qlt Inc | 涙管インプラント及び関連する方法 |
JP2014236980A (ja) * | 2007-09-07 | 2014-12-18 | キュー エル ティー インク.QLT Inc. | 治療薬剤の持続放出のための薬物コア |
KR20150136140A (ko) * | 2007-09-07 | 2015-12-04 | 마티 테라퓨틱스 인코포레이티드 | 치료 약제의 서방성 약물 코어 |
JP2016165503A (ja) * | 2007-09-07 | 2016-09-15 | マティ セラピューティクス,インク. | 治療薬剤の持続放出のための薬物コア |
JP2011520805A (ja) * | 2008-05-09 | 2011-07-21 | キューエルティー プラグ デリバリー,インク. | 緑内障および高眼圧症治療のための活性剤の持続送達 |
JP2012512725A (ja) * | 2008-12-19 | 2012-06-07 | キュー エル ティー インク. | 物質送達用涙点インプラントおよび物質送達方法 |
JP2012514493A (ja) * | 2009-01-02 | 2012-06-28 | アルコン リサーチ, リミテッド | その場で再充填可能な眼用移植物 |
JP2013523821A (ja) * | 2010-04-06 | 2013-06-17 | アラーガン、インコーポレイテッド | 前房内薬剤送達のための徐放性リザーバーインプラント |
CN110730655A (zh) * | 2017-06-13 | 2020-01-24 | 视点制药公司 | 可生物侵蚀的药物递送装置 |
JP2020529390A (ja) * | 2017-06-13 | 2020-10-08 | アイポイント ファーマシューティカルズ,インコーポレイティドEyePoint Pharmaceuticals, Inc. | 生体浸食性薬物送達デバイス |
JP7278223B2 (ja) | 2017-06-13 | 2023-05-19 | アイポイント ファーマシューティカルズ,インコーポレイティド | 生体浸食性薬物送達デバイス |
CN110730655B (zh) * | 2017-06-13 | 2024-03-05 | 视点制药公司 | 可生物侵蚀的药物递送装置 |
Also Published As
Publication number | Publication date |
---|---|
EP1592408B1 (en) | 2009-08-26 |
CA2513751A1 (en) | 2004-08-12 |
ATE440595T1 (de) | 2009-09-15 |
BRPI0406879A (pt) | 2006-01-03 |
TWI356714B (en) | 2012-01-21 |
BRPI0406879B1 (pt) | 2015-12-22 |
WO2004066979A2 (en) | 2004-08-12 |
TW200500099A (en) | 2005-01-01 |
EP1592408A2 (en) | 2005-11-09 |
ES2332720T3 (es) | 2010-02-11 |
DE602004022776D1 (de) | 2009-10-08 |
WO2004066979A3 (en) | 2004-09-16 |
AR042917A1 (es) | 2005-07-06 |
AU2004207506B2 (en) | 2009-10-08 |
KR20050118161A (ko) | 2005-12-15 |
MXPA05007719A (es) | 2005-09-30 |
CA2513751C (en) | 2012-01-10 |
SI1592408T1 (sl) | 2010-01-29 |
DK1592408T3 (da) | 2010-01-04 |
AU2004207506A1 (en) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006516618A (ja) | アドレナリン作動薬を眼へ輸送するために徐放性デバイス及び方法 | |
US20040208910A1 (en) | Sustained release device and method for ocular delivery of adrenergic agents | |
JP2006516619A (ja) | 炭酸脱水酵素阻害剤を眼へ輸送するために徐放性デバイス及び方法 | |
US20040175410A1 (en) | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors | |
JP4705304B2 (ja) | 徐放性薬剤送達システム、使用方法、およびその製造方法 | |
CN102905688B (zh) | 用于前房内药物递送的缓释储库式植入物 | |
CA2432203C (en) | Sustained release drug delivery devices with multiple agents | |
CN102014817B (zh) | 用于控释活性剂的眼科装置 | |
EA002162B1 (ru) | Способ лечения организма млекопитающего, способ обеспечения регулируемого и длительного введения средства, устройство доставки для длительного высвобождения лекарственного препарата | |
US20110251568A1 (en) | Punctal plugs for controlled release of therapeutic agents | |
KR20120027167A (ko) | 누점 마개 | |
KR20120013346A (ko) | 누점 마개 | |
PT109154A (pt) | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos | |
CN100594899C (zh) | 经眼部递送碳酸酐酶抑制剂的持续释放系统和方法 | |
US20110301555A1 (en) | Porous matrix drug core for lacrimal insert device | |
KR20070121555A (ko) | 활성제 전달용 누점 플러그 | |
BR112018016301B1 (pt) | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100511 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100811 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110913 |